适形放疗同期吉西他滨化疗综合治疗老年Ⅲ期非小细胞肺癌
Concurrent Gemcitabine Chemotherapy and 3D-CRT for Elderly Advanced Non-small Cell Lung Cancer
-
摘要: 目的评价X线三维适形放疗(3DCRT)并同期吉西他滨(泽菲)化疗综合治疗Ⅲ期老年非小细胞肺癌(NSCLC)的疗效及毒副作用。方法65例Ⅲ期老年非小细胞肺癌(NSCLC)患者随机分为2组:治疗组35例,行全程X线三维适形放疗DT(40～52)Gy/(3～4)周,(3～4)Gy/次,5次/周;化疗,泽菲1000mg/m2,每周1次,连3周(第1、8、15天静点)。对照组30例,只行三维适形放射治疗,具体剂量、分割方式同治疗组。治疗完成后评价疗效和不良反应。结果治疗组总有效率(CR+PR)74.29%,完全缓解率(CR)22.85%;对照组总有效率50.00%,完全缓解率10.00%,两组间总有效率差异有显著性(χ2=4.09,P=0.043)。中位生存期治疗组和对照组分别为13个月和11个月,1、2年生存率治疗组分别为60%、33.33%;对照组分别为50%、23.33%,两组间差异无显著性(P>0.05)。放化疗的毒副反应主要是消化道反应、骨髓抑制、放射性肺炎和放射性食管炎,但皆可耐受。结论全程X线三维适形放疗并同期泽菲化疗综合治疗Ⅲ期老年非小细胞肺癌(NSCLC)可明显提高近期疗效,远期疗效略有提高,但无统计...Abstract: Objective To evaluate the therapeutic effectiveness and adverseevents of concurrent gemcitabine chemotherapy and 3-dimentional conformalradiotherapy (3D-CRT) for elderly advanced non-small cell lung cancer(NSCLC). Methods 65 patients of stage Ⅲ NSCLC were enrolled into twogroups: 35cases in the treatment group received concurrent chemotherapy(gemcitabine 1000mg/m2/w, continuous 3 weeks) and 3D-CRT: were given,(3~4)Gyper fractions,5 fraction a week,to total dose of (40~52) Gy/(3~4) week.30 casesin the control...
下载:
